Definitive Contract HHSO100201000034C

This is a definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Biodefense Operations Lansing LLC, a for-profit manufacturer of medical countermeasures. The $1,174,464,339.10 firm fixed-price contract is for the production of BioThrax, the only FDA-licensed vaccine for the prevention of anthrax disease, which is a critical component of the U.S. government's strategic national stockpile. The...

This is a $99,941,719.80 definitive, firm fixed-price contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Emergent Biodefense Operations Lansing LLC, doing business as Emergent Biodefense, on March 16, 2017. The contract has an ultimate completion date of March 15, 2019 and is not set aside. Emergent Biodefense is a for-profit manufacturer of medical countermeasures and biopharmaceuticals, specializing in vaccines and therapeutics for public health...

This federal contract award is for BAXTER CELL HARVEST services in year 6 of the contract, awarded by the Centers for Disease Control and Prevention (CDC) Pittsburgh to Emergent Biodefense Operations Lansing LLC, doing business as Emergent Biodefense. The contract has a ceiling value of $38,250,000.00 and was awarded on September 30, 2016, with an ultimate completion date of August 31, 2018. It is a Firm Fixed Price delivery order contract. Emergent Biodefense is a for-profit manufacturer of...

This federal contract was awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Biodefense Operations Lansing LLC for WETVAX POTENCY TESTING. The contract has a potential value of $136,612.00 and is a Firm Fixed Price Purchase Order. The place of performance is Canton, MA 02021, USA. The contract does not have a set-aside designation. As the awardee, Emergent Biodefense Operations Lansing LLC is a for-profit...

This is a firm fixed price delivery order awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency under the Department of Health and Human Services (HHS), to Emergent Manufacturing Operations Baltimore LLC, a for-profit manufacturer of medical countermeasures. The $196,434,000 award is for the provision of anthrax antitoxins to treat inhalational anthrax, under the agency's medical countermeasures development and procurement program. The...

The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded a Firm Fixed Price Purchase Order contract to Emergent Biodefense Operations Lansing LLC for the WETVAX 2021 project. The contract has a potential value of $141,400.00 and a completion date of August 31, 2021. The contract does not have a set-aside designation. Emergent Biodefense Operations Lansing LLC is the prime contractor for this award, which is likely related to the agency's...

The U.S. Department of Health and Human Services (HHS), through the Office of the Assistant Secretary for Preparedness and Response (ASPR), awarded a $630,384,987.00 firm-fixed-price definitive contract to Emergent BioDefense Operations Lansing LLC for the advanced research and development of a smallpox antiviral drug. This award is not associated with a set-aside contract and is part of ASPR's broader efforts to procure and stockpile alternative smallpox antivirals. The original procurement was...

This is a $43,794,113.43 cost-plus-fixed-fee definitive contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response to Emergent Product Development Gaithersburg Inc., a for-profit manufacturer, for the advanced development of NuThrax (Anthrax Vaccine Absorbed with CPG 7909) or AV7909. The contract has an ultimate completion date of July 31, 2019 and was awarded on March 23, 2015. There is no set-aside designation for this...

<p>This is a $135,895.50 firm fixed price purchase order awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to Emergent Biodefense Operations Lansing LLC for the annual potency testing of the WETVAX (APSV) vials stored at the Strategic National Stockpile (SNS). The contract has an end date of August 31, 2022 and was awarded on May 12, 2022. No set-aside was used for this procurement.</p>

The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a definitive firm fixed price contract valued at $7.4 million to Siga Technologies, Inc. of New York. The contract is to procure 10,000 courses of the FDA-approved smallpox therapeutic tecovirimat, also known as TPOXX, to replenish expiring stock within the Department of Defense stockpile. The solicitation was a sole source combined synopsis/solicitation for TPOXX as the only FDA-approved...